BR112023026782A2 - Formulações de proteínas quiméricas de fator viii e usos das mesmas - Google Patents
Formulações de proteínas quiméricas de fator viii e usos das mesmasInfo
- Publication number
- BR112023026782A2 BR112023026782A2 BR112023026782A BR112023026782A BR112023026782A2 BR 112023026782 A2 BR112023026782 A2 BR 112023026782A2 BR 112023026782 A BR112023026782 A BR 112023026782A BR 112023026782 A BR112023026782 A BR 112023026782A BR 112023026782 A2 BR112023026782 A2 BR 112023026782A2
- Authority
- BR
- Brazil
- Prior art keywords
- factor viii
- chimerical
- protein formulations
- viii protein
- polypeptide
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108010054218 Factor VIII Proteins 0.000 abstract 2
- 102000001690 Factor VIII Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010047303 von Willebrand Factor Proteins 0.000 abstract 2
- 102100036537 von Willebrand factor Human genes 0.000 abstract 2
- 229960001134 von willebrand factor Drugs 0.000 abstract 2
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214246P | 2021-06-23 | 2021-06-23 | |
| US202163214245P | 2021-06-23 | 2021-06-23 | |
| US202163214752P | 2021-06-24 | 2021-06-24 | |
| US202163231909P | 2021-08-11 | 2021-08-11 | |
| PCT/US2022/034747 WO2022271962A1 (en) | 2021-06-23 | 2022-06-23 | Formulations of factor viii chimeric proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023026782A2 true BR112023026782A2 (pt) | 2024-03-12 |
Family
ID=82656587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023026782A BR112023026782A2 (pt) | 2021-06-23 | 2022-06-23 | Formulações de proteínas quiméricas de fator viii e usos das mesmas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240287158A1 (https=) |
| EP (1) | EP4358938A1 (https=) |
| JP (1) | JP2024522855A (https=) |
| KR (1) | KR20240024949A (https=) |
| AU (1) | AU2022298798A1 (https=) |
| BR (1) | BR112023026782A2 (https=) |
| CA (1) | CA3220564A1 (https=) |
| CO (1) | CO2023017358A2 (https=) |
| IL (1) | IL309309A (https=) |
| MX (1) | MX2023015238A (https=) |
| TW (1) | TW202317178A (https=) |
| WO (1) | WO2022271962A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023172893A2 (en) * | 2022-03-08 | 2023-09-14 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2124690C (en) * | 1992-10-02 | 2007-09-11 | Thomas Osterberg | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
| MX339060B (es) * | 2008-11-07 | 2016-05-09 | Baxter Int | Formulaciones del factor viii. |
| CN104661674A (zh) | 2012-07-11 | 2015-05-27 | 阿穆尼克斯运营公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
| AU2015204646B2 (en) | 2014-01-10 | 2020-08-27 | Bioverativ Therapeutics Inc. | Factor VIII chimeric proteins and uses thereof |
| PL3793588T3 (pl) * | 2018-05-18 | 2025-09-01 | Bioverativ Therapeutics Inc. | Sposoby leczenia hemofilii a |
| CN114007637A (zh) * | 2019-06-19 | 2022-02-01 | 比奥维拉迪维治疗股份有限公司 | 用于治疗血友病和低骨矿物质密度的重组因子viii-fc |
| US20220305089A1 (en) * | 2019-08-16 | 2022-09-29 | Octapharma Ag | Stabilizing buffer for factor viii and vwf |
-
2022
- 2022-06-23 US US18/572,006 patent/US20240287158A1/en active Pending
- 2022-06-23 TW TW111123492A patent/TW202317178A/zh unknown
- 2022-06-23 EP EP22744880.0A patent/EP4358938A1/en active Pending
- 2022-06-23 MX MX2023015238A patent/MX2023015238A/es unknown
- 2022-06-23 WO PCT/US2022/034747 patent/WO2022271962A1/en not_active Ceased
- 2022-06-23 JP JP2023579138A patent/JP2024522855A/ja active Pending
- 2022-06-23 IL IL309309A patent/IL309309A/en unknown
- 2022-06-23 BR BR112023026782A patent/BR112023026782A2/pt unknown
- 2022-06-23 KR KR1020247002191A patent/KR20240024949A/ko active Pending
- 2022-06-23 AU AU2022298798A patent/AU2022298798A1/en active Pending
- 2022-06-23 CA CA3220564A patent/CA3220564A1/en active Pending
-
2023
- 2023-12-14 CO CONC2023/0017358A patent/CO2023017358A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4358938A1 (en) | 2024-05-01 |
| AU2022298798A1 (en) | 2024-02-08 |
| CA3220564A1 (en) | 2022-12-29 |
| TW202317178A (zh) | 2023-05-01 |
| US20240287158A1 (en) | 2024-08-29 |
| CO2023017358A2 (es) | 2024-01-15 |
| MX2023015238A (es) | 2024-03-08 |
| IL309309A (en) | 2024-02-01 |
| WO2022271962A1 (en) | 2022-12-29 |
| JP2024522855A (ja) | 2024-06-21 |
| KR20240024949A (ko) | 2024-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091735A1 (es) | Complejo de factor viii con xten y proteina factor de von willebrand (vwf) y usos del mismo | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| ZA202501799B (en) | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications | |
| MX2021003554A (es) | Proteinas de union a dll3 y metodos de uso. | |
| BR112016015512A2 (pt) | proteínas quiméricas de fator viii e suas utilizações | |
| AR089324A1 (es) | Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas | |
| BR112018071200A2 (pt) | terapia genética para o tratamento da hemofilia a | |
| ATE549028T1 (de) | Stabile analoga von glp-1 | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| ATE442373T1 (de) | Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden | |
| BRPI0512286A (pt) | proteìnas quiméricas inibidoras da angiogênese e o uso | |
| CO2023000048A2 (es) | Conjugados de citoquina | |
| BR112022017032A2 (pt) | Composições compreendendo ltb e antígenos patogênicos, e uso das mesmas. | |
| BR112023026782A2 (pt) | Formulações de proteínas quiméricas de fator viii e usos das mesmas | |
| CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
| DE602004028246D1 (de) | Analoga von peptiden der relaxin-superfamilie | |
| ZA202403355B (en) | Single domain antibodies binding to tetanus neurotoxin | |
| ATE177843T1 (de) | Peptomere mit erhöhter immunogenizität | |
| CO2024004211A2 (es) | Formulaciones de proteínas quiméricas de factor viii y usos de las mismas | |
| BR112023022367A2 (pt) | Anticorpos anti-tigit e métodos de uso dos mesmos | |
| Pavirani et al. | Advances in biotechnology of factor VIII | |
| EA202192147A1 (ru) | Каркасы мембранных белков для конструирования экзосом | |
| BR112022003498A2 (pt) | Peptídeos recombinantes do tipo elastina imunotolerantes e métodos de uso | |
| BR112023002484A2 (pt) | Vacinas anticoronavírus | |
| DOP2024000066A (es) | Dendrones peptídicos y métodos de uso de los mismos |